PubMed · 1408553
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
M Lewis, D S Ramsay, S J Suomi. 1992. Validating current immunization practice with young infants.. https://pubmed.ncbi.nlm.nih.gov/1408553/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
OBJECTIVE: To compare the immunogenicity of polysaccharide-conjugate vaccines with that of polysaccharide vaccines in patients previously treated for Hodgkin disease. DESIGN: All patients were immunized with Haemophilus influenzae type b (HIB)-conjugate and 4-valent meningococcal polysaccharide vaccines. Subgroups of patients were randomly assigned to receive either 23-valent pneumococcal polysaccharide vaccine or a 7-valent pneumococcal-conjugate vaccine that links seven pneumococcal serotypes to the outer membrane protein complex of Neisseria meningitidis. PATIENTS: 144 patients who had completed treatment for Hodgkin disease, which had been diagnosed at least 2 years before the study. MEASUREMENTS: Antigen-specific antibody concentrations before and 3 to 6 weeks after immunization; number of persons who achieved anti-HIB antibody concentrations considered to be in the protective range. RESULTS: The geometric mean anti-HIB antibody concentration increased from 1.79 micrograms/mL before immunization to 54.1 micrograms/mL after; the percentage of persons with antibody concentrations in the protective range increased from 62% before immunization to 99% after. Patients immunized with 23-valent pneumococcal vaccine had a geometric mean pneumococcal antibody concentration after immunization (9.15 micrograms/mL) that was similar to that of healthy controls (10.0 micrograms/mL) for the seven serotypes measured. In contrast, patients who received 7-valent pneumococcal-conjugate vaccine had a significantly lower mean response compared with patients who received 23-valent; their geometric mean antibody concentration after immunization was 4.95 micrograms/mL (P = 0.005). CONCLUSION: A single dose of HIB-conjugate vaccine was immunogenic in patients who had completed treatment for Hodgkin disease diagnosed at least 2 years before immunization. In addition, responses to the 23-valent pneumococcal and 4-valent meningococcal vaccines were equivalent to those seen in healthy controls. Finally, patients had a significantly lower response to a single dose of 7-valent pneumococcal-conjugate vaccine than to 23-valent vaccine.
Capsular polysaccharide (CPS) was obtained by water-saline extraction of the Alteromonas sp. CMM 155. On the basis of solvolysis with anhydrous HF and 1H- and 13C-NMR spectral data, including NOE experiments, it was concluded that the capsular polysaccharide had the following structure containing novel N-acyl-amino sugar and bacillosamine residues: --> 3)-alpha-D-GalpNAc-(1 --> 4)-alpha-L-GalApNAc(1 --> 3)- alpha-D-QuipNAc4NAc-(1 --> 3)-beta-D-Quip4NAlaAc-(1 -->
The structure of the capsular polysaccharide elaborated by Klebsiella type 7 has been investigated. NMR spectroscopy together with sugar and methylation analysis have been the main methods used. A uronic acid degradation was also employed. The polysaccharide consists of hexasaccharide repeating units having the following structure. [formula: see text]